These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9332322)

  • 21. Heparinoid anticoagulation and topical fibrin sealant in heparin-induced thrombocytopenia.
    Jackson MR; Danby CA; Alving BM
    Ann Thorac Surg; 1997 Dec; 64(6):1815-7. PubMed ID: 9436582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
    Grocott HP; Root J; Berkowitz SD; deBruijn N; Landolfo K
    J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):875-7. PubMed ID: 9412888
    [No Abstract]   [Full Text] [Related]  

  • 23. Danaparoid sodium.
    Acostamadiedo JM; Iyer UG; Owen J
    Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
    Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
    Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticoagulative management of patients requiring left ventricular assist device implantation and suffering from heparin-induced thrombocytopenia type II.
    Christiansen S; Jahn UR; Meyer J; Scheld HH; Van Aken H; Kehrel BE; Hammel D
    Ann Thorac Surg; 2000 Mar; 69(3):774-7. PubMed ID: 10750760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical experiences with Danaparoid sodium. Measures to be taken in heparin-induced thrombocytopenia].
    Anaesthesist; 1998 Nov; 47(11 Suppl Massnahmen):1-4. PubMed ID: 9884734
    [No Abstract]   [Full Text] [Related]  

  • 28. Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses.
    Tardy B; Tardy-Poncet B; Viallon A; Piot M; Mazet E
    Thromb Haemost; 1998 Sep; 80(3):530. PubMed ID: 9759647
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
    Gill J; Kovacs MJ
    Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of Organon, a synthetic heparinoid, in two cardiopulmonary bypass procedures in the same patient sensitive to heparin].
    Pineau E; Le Bret E; Folliguet T; Saint Maurice OS; Carbognani D; Laborde F
    Arch Mal Coeur Vaiss; 2001 Feb; 94(2):144-7. PubMed ID: 11265553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
    Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
    Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
    Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heparin-induced thrombocytopenia and its treatment.
    Warkentin TE
    J Thromb Thrombolysis; 2000 Jun; 9 Suppl 1():S29-35. PubMed ID: 10859582
    [No Abstract]   [Full Text] [Related]  

  • 34. Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome.
    Tardy/Poncet B; Mahul P; Beraud AM; Favre JP; Tardy B; Guyotat D
    Br J Haematol; 1995 Aug; 90(4):969-70. PubMed ID: 7669684
    [No Abstract]   [Full Text] [Related]  

  • 35. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
    Magnani HN; Gallus A
    Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Heparin induced thrombocytopenia: case report with acute thrombotic complications and literature review].
    Plassat R; Cognet F; Ternisien C; Ménoret N; Dubus-Bausière V; Brunel P; Bontoux L; Bernat C; Richard I
    Ann Readapt Med Phys; 2002 May; 45(5):216-23. PubMed ID: 12020989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
    Lindhoff-Last E; Bauersachs R
    Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonheparin anticoagulants for heparin-induced thrombocytopenia.
    Kelton JG; Arnold DM; Bates SM
    N Engl J Med; 2013 Feb; 368(8):737-44. PubMed ID: 23425166
    [No Abstract]   [Full Text] [Related]  

  • 39. Heparin-induced thrombocytopenia (HIT): in vitro and in vivo cross-reactivity to danaparoid sodium and successful treatment with recombinant hirudin (lepirudin).
    Baumgärtel MW; Eichler P; Glöckner WM; Ranze O; Greinacher A
    Eur J Haematol; 2000 Aug; 65(2):148-9. PubMed ID: 10966178
    [No Abstract]   [Full Text] [Related]  

  • 40. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
    Carrier M; Robitaille D; Perrault LP; Pellerin M; Pagé P; Cartier R; Bouchard D
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):325-9. PubMed ID: 12579101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.